Sven de Vos, MD, PhD

What is New in the Approach to DLBCL Upfront and in the Relapsed Setting?

03/10/2020

ZUMA-12: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel as a First-Line Therapy in Patients With High-Risk Large B Cell Lymphoma

Purpose of the Study: Patients with large B cell lymphoma (LBCL) who have persistent disease assessed by dynamic positron emission tomography after rituximab-based induction therapy have ...

Jun Kawashima ;

Alex F. Herrera ;

Sven de Vos , MD, PhD;

Sattva S. Neelapu ;

Julio C. Chavez ;

Yi Lin ;

Javier Munoz ;

Lovely Goyal ;

Chaitra S. Ujjani ;

Peter Riedell ;

Olalekan O. Oluwole ;

Natasha Kekre ;

Kate Backhouse ;

Francesca Milletti ;

10/22/2019

Subcutaneous Epcoritamab Combined With Rituximab + Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update

Introduction:

Jacob H. Christensen ;

Sven de Vos , MD, PhD;

Harald Holte ;

Kim M. Linton ;

Aqeel Abbas ;

Minh Dinh ;

Brian Elliott ;

David Belada ;

Sirpa Leppä, ;

Lorenzo Falchi ;

Bjorn E. Wahlin ;

Marcel Nijland ;

11/04/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8 ⁠–⁠ November 10

November 8

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Sven de Vos, MD, PhD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products